Neffy nasal spray shows comparable efficacy to IM epinephrine for type I allergic reactions, with 92.3% symptom resolution after 1 dose.

Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic cough treatment gap.

Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Patients with hereditary angioedema report significant unmet needs, including high costs and insurance barriers, according to data from AAAAI 2026.

Aspirin 81mg tabs, 325mg caplets; e-c. To reduce combined risk of death and nonfatal stroke after ischemic stroke or TIA. To reduce risk of vascular mortality in suspected acute MI. To reduce combined ...

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.

A retrospective cohort study of 210,000 pediatric patients showed ICS therapy did not elevate the risk for pediatric fractures.

New data reveal that episodic lack of disease control in chronic spontaneous urticaria is linked to increased hospitalizations and outpatient visits.

Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.